Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMF8U0)

• Drug Name: Atezolizumab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25	Approved	[1]
Bladder cancer	2C94	Phase 3	[2]
Breast cancer	2C60-2C65	Phase 3	[2]
Hepatocellular carcinoma	2C12.02	Phase 3	[2]
Ovarian cancer	2C73	Phase 3	[2]
Prostate cancer	2C82.0	Phase 3	[2]
Renal cell carcinoma	2C90	Phase 3	[2]
Small-cell lung cancer	2C25.Y	Phase 3	[2]
Squamous cell carcinoma	2B60-2D01	Phase 3	[2]
Urothelial carcinoma	2C92.0	Phase 3	[2]
Acute myeloid leukaemia	2A60	Phase 1	[2]
Colorectal cancer	2B91.Z	Phase 1	[2]
Follicular lymphoma	2A80	Phase 1	[2]
Gastric adenocarcinoma	2B72	Phase 1	[2]
Haematological malignancy	2B33.Y	Phase 1	[2]
Melanoma	2C30	Phase 1	[3]
Multiple myeloma	2A83	Phase 1	[2]
Myelodysplastic syndrome	2A37	Phase 1	[2]
Pancreatic cancer	2C10	Phase 1	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
Bronchioalveolar carcinoma	2C25.0	Phase 0	[5]
Ulcer	CA02-CB40	Phase 0	[5]
Transitional cell carcinoma		Investigative	[6]

• Cross-matching ID: TTD Drug ID: DMMF8U0

Molecule-Related Drug Atlas

Drug(s) Targeting Programmed cell death 1 ligand 1 (PD-L1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Avelumab	DMSZLJR	Merkel cell carcinoma	2C34	Approved	[7]
Durvalumab	DM4PVDY	Urothelial carcinoma	2C92.0	Approved	[8]
RG-7446	DM69XMQ	Urothelial carcinoma	2C92.0	Approved	[9]
Bavencio	DMU9C8F	Merkel cell carcinoma	2C34	Approved	[10]
Sugemalimab	DMH5YQ3	Non-small-cell lung cancer	2C25	Approved in China	[11]
KN046	DMSDBPG	Non-small-cell lung cancer	2C25.Y	Phase 3	[12]
MEDI4736	DM5X849	Solid tumour/cancer	2A00-2F9Z	Phase 3	[13]
MPDL-3280A	DM9K3LM	Melanoma	2C30	Phase 3	[14]
CS1001	DMSY0NE	Non-small-cell lung cancer	2C25	Phase 3	[15]
A167	DME00MM	Nasopharyngeal carcinoma	2B6B	Phase 3	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Programmed cell death 1 ligand 1 (PD-L1)	TT8ZLTI	PD1L1_HUMAN	Not Available	[1]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
• [6] Atezolizumab-associated vitiligo-like leukoderma in a patient with transitional cell carcinoma. Int J Dermatol. 2018 Oct;57(10):e90-e92.
• [7] Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-57.
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [9] PD-1 as a potential target in cancer therapy. Cancer Med. 2013 October; 2(5): 662-673.
• [10] ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health.
• [11] Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.
• [12] Clinical pipeline report, company report or official report of Alphamab Oncology.
• [13] National Cancer Institute Drug Dictionary (drug id 740856).
• [14] Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2): 39-47.
• [15] GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015.
• [16] Clinical pipeline report, company report or official report of Klus Pharma